Table 1. Analysis of p53 and p^19ARF sequence in tumor samples.

Exons 5–10 of p53 genomic DNA and exons 2–11 of p53 cDNA were PCR amplified and sequenced. The coding sequence of p19^ARF was amplified and sequenced (exons 1–3) from cDNA samples. All sequencing was performed multiple times and PCR products were sequenced in both directions.

p53 exon amplification from genomic DNA
ID	genotype	tumor type	Ex. 5	Ex. 6	Ex.7	Ex. 8	Ex. 9	Ex. 10
22790	M-C2	basal carcinoma	WT	WT	WT	WT	WT	WT
23186	N-C2	adeno/squamous carcinoma	WT	WT	WT	WT	WT	WT
23182	M-C2	osteosarcoma	WT	WT	WT	WT	WT	WT
23828	N-C2	granulosa cell tumor	WT	WT	WT	WT	WT	WT
21872	N-C2	histiocytic sarcoma	WT	WT	WT	WT	WT	WT
23646	N-C2	lymphoma	WT	WT	WT	WT	WT	WT
23649	N-C2	mammary carcinoma	WT	WT	WT	WT	WT	ND
24098	N-C2	basal carcinoma	WT	WT	WT	WT	WT	WT

p53 and p19ARF amplification from cDNA
ID		tumor type	p53 Cdna exons 2–11	p19ARF cDNA exons 1–3
23902	M-C2	basal carcinoma	WT	NA
24071	N-C2	lymphoma	WT	NA
23828	N-C2	granulosa cell tumor	WT	WT
23129	M-C2	histiocytic sarcoma	WT	WT
23186	N-C2	adeno/squamous carcinoma	WT	WT
25094	N-C2	uterine leiomyosarcoma	WT	WT
23646	N-C2	lymphoma	WT	WT

(M-C2=Mre11^ATLD1/ATLD1 Chk2^−/−, N-C2=Nbs1^ΔB/ΔB Chk2^−/−, WT=wild type, ND=not determined, NA=not amplifiable)